Todd Davis Purchases 35,948 Shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Todd Davis bought 35,948 shares of Pelthos Therapeutics stock in a transaction on Thursday, June 11th. The stock was acquired at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the acquisition, the director owned 75,834 shares in the company, valued at approximately $2,109,701.88. This represents a 90.13% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Pelthos Therapeutics Trading Up 5.7%

Pelthos Therapeutics stock opened at $28.02 on Wednesday. The company has a market cap of $97.51 million, a price-to-earnings ratio of -1.36 and a beta of 3.16. The business has a fifty day simple moving average of $25.37. Pelthos Therapeutics Inc. has a 12 month low of $11.20 and a 12 month high of $54.29. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its earnings results on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The business had revenue of $10.91 million during the quarter. On average, equities research analysts forecast that Pelthos Therapeutics Inc. will post -11.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Pelthos Therapeutics

Several large investors have recently made changes to their positions in the business. Pale Fire Capital SE lifted its position in shares of Pelthos Therapeutics by 59.5% in the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after acquiring an additional 4,819 shares in the last quarter. Knott David M Jr lifted its position in shares of Pelthos Therapeutics by 9.3% in the first quarter. Knott David M Jr now owns 21,073 shares of the company’s stock valued at $443,000 after acquiring an additional 1,792 shares in the last quarter. Ikarian Capital LLC lifted its position in shares of Pelthos Therapeutics by 309.5% in the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after acquiring an additional 193,307 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Pelthos Therapeutics in the fourth quarter valued at about $343,000. Finally, Boothbay Fund Management LLC lifted its position in shares of Pelthos Therapeutics by 279.8% in the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock valued at $2,501,000 after acquiring an additional 59,435 shares in the last quarter. 77.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on PTHS shares. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Zacks Research raised Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. Oppenheimer lifted their price objective on Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Roth Mkm cut their price objective on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Finally, Piper Sandler started coverage on Pelthos Therapeutics in a report on Friday, February 27th. They issued an “overweight” rating and a $48.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Pelthos Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.80.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).